OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
New data suggests there is no connection between ustekinumab and the risk of malignancies.
While the majority of data that has come out about the safety on ustekinumab for patients with inflammatory bowel disease (IBD).
But there is always a need for more and more safety data.
In an interview with HCPLive®, Millie D. Long, MD, MPH, FACG, University of North Carolina, said despite some really positive data on the treatment, investigators should always be looking at long-term safety data.
“I’m always a proponent of further safety data. The longer we follow patients on this therapy the more we know,” Long said. “That way we can ensure there is no evidence of rare outcomes.”
In new data presented during 2022 Digestive Disease Week Annual Meeting in San Diego, a team, led by Long, found little evidence of malignancies following ustekinumab treatment for patients with ulcerative colitis and psoriatic arthritis.
In the study, the investigators followed 6710 patients treated with ustekinumab for up to 5 years, involving 13,807 years of follow-up and found an incidence rate of patients with at least 1 malignancies per 100 patient-years for all malignancies was 1.00 (95% CI, 0.84-1.118), compared to 0.73 for the placebo group.
Long also talked about what goes into advising patients on treatments should they have a reaction to ustekinumab. Largely, she said this is based on the individual circumstances of the patients.